ImmunityBio Sponsored Study Atezolizumab And N-803 After Progression On Any Immune Checkpoint Blocker In NSCLC Posted To Clinical Trials Website Not Yet Recruiting
https://clinicaltrials.gov/ct2/show/NCT05007769
Stocks That Hit 52-Week Lows On Monday
Stocks That Hit 52-Week Lows On Monday
Monday morning, 285 companies reached new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday
During the morning session on Thursday, 152 stocks hit new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday
Thursday morning, 158 companies reached new 52-week lows.
Cramer Weighs In On Cloudflare, MP Materials And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said he should talk more about Cloudflare Inc (NYSE: NET) on the show because it has got a great security component and it's doing incredibly wel
ImmunityBio Highlights Publication In Journal for Immunotherapy of Cance
The "neoepitope" identification pipeline facilitates discovery of immunotherapy targets unique to individual cancer patients as a personalized and precision medicine approach to treatment
The neoepitopes
ImmunityBio Files For U.S. Patent Titled ‘NK-92 Cells to Stimulate Anti-Cancer Vaccine’
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=8797&p=176&f=G&l=50&d=PG01&S1=20210624.PD.&OS=PD/20210624&RS=PD/20210624
FDA Authorizes ImmunityBio’s Study Of Anktiva And PD-L1 t-haNK To Increase Effectiveness Of Trodelvy In Triple-Negative Breast Cancer
Open-label Phase 1b/2 study will evaluate the safety and preliminary efficacy of Anktiva (N-803) and PD-L1 t-haNK in combination with antibody-drug conjugate Trodelvy and low-dose chemotherapy in subjects